Join the leaders in STING & TLR therapies
We are excited to release the agenda for the Innate Immune Stimulating Therapies Summit, running virtually on Wednesday, July 22 at 09.00 Eastern Time.
Join the first multi-disciplinary discussion with industry leaders to discuss how to achieve safe and effective clinical and commercial translation of STING and TLR therapies. Check out the official event guide for full speaker details: https://ter.li/4y341g
Just some of the experts who will share their latest findings and lessons learned:
- Marc Damelin, Executive Director and Head of Biology, Mersana Therapeutics Inc
- Arthur Krieg, Chief Scientific Officer, Checkmate Pharmaceuticals
- Kimberly Schluns, Associate Professor, University of Texas MD Anderson Cancer Center
- Valerie Odegard, Chief Scientific Officer, Silverback Therapeutics
- Xingfeng Bao, Senior Director, Immuno-Oncology, H3biomedicine
- Glen Barber, Professor of the Department of Cell Biology, University of Miami Miller School of Medicine
- Michael Adams, Investigator, GlaxoSmithKline
Join the growing list of companies already confirmed to attend, including AbbVie, Ambrx, Aduro Biotech, Boehringer Ingelheim, CytomX Therapeutics, Daiichi-Sankyo, Decoy Biosystems, H3biomedicine, Merck, Seattle Genetics, West Pharma, Zymeworks and many more!
There are no doubt many clinical challenges to overcome in realizing the full potential of STING and TLR therapies. Join us online to share best practice, clinical progress and lessons learned on the journey so far to translate safe and effective innate immune stimulating therapies for patients in need.
Register online this week and save $200 on your ticket, plus an additional 10% saving when you quote VIP Code 17233PJEM: https://ter.li/glyita